Swixx BioPharma - Therapeutic and Geographic Focus

FOCUS

Swixx BioPharma GEOGRAPHIC AND THERAPEUTIC FOCUS While today Swixx BioPharma is primarily focused on the CEE region, Swixx BioPharma anticipates to further expand to Russia / CIS countries, and later possibly to Western Europe, Middle East or Africa. That said, Swixx BioPharma’s focus is in the following therapeutic areas: • Modern, high tech, professionally-positioned products with a compelling medical proposition (evidence based medicine / significant clinical impact), especially in oncology/hematology, nephrology, transplantation medicines, GI and other specialty. • Rare disease / orphan medicines - new, dedicated business unit formed as of December, 2018 • OTCs / Open Market preferably established brands or products with Unique Selling Propositions • Out of pocket / largely non-reimbursed products, in areas of critical unmet needs • Products with rapid regulatory pathways: Medical Devices / Food Supplements / Cosmetics and products with existing registrations • Selective Purchase of existing brands or platforms that carefully complement our partners portfolios

Swixx BioPharma is focused on CEE region • Albania • Bosnia and Herzegovina • Belarus • Bulgaria • Croatia • Czech Republic • Estonia • Greece • Hungary • Kazakhstan • Kosovo • Latvia • Lithuania • Moldova • Montenegro • North Macedonia • Poland • Romania • Russia • Serbia • Slovakia • Slovenia • Uzbekistan

This region comprise 275 million people and a pharmaceutical market of 50+ billion Euros. Their economies currently are amongst the least developed in Europe, but they show considerable promise and boast well-educated and cultured people. Many western healthcare companies chose not to enter these markets, but nonetheless wish to have their products present and represented by a professional, compliant and competent regional partner. Swixx BioPharma aims to fill this need and to bring modern medicines to the people of the region.